AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...

FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca's Fasenra ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca's Fasenra ...

5,7 Patients were randomized to receive either a single 30 mg subcutaneous injection of FASENRA, or three separate 100 mg subcutaneous injections of mepolizumab every four weeks. 4,5 In the trial ...

AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...

Injection site reactions (eg, pain, erythema, pruritus, papule) occurred at a rate of 2.2% in patients treated with FASENRA compared with 1.9% in patients treated with placebo in asthma ...

5,7 Patients were randomized to receive either a single 30 mg subcutaneous injection of FASENRA, or three separate 100 mg subcutaneous injections of mepolizumab every four weeks.4,5 In the trial, ...

Image Source: Zacks Investment Research The FDA nod for Fasenra in EGPA was based on data from the phase III MANDARA study. The MANDARA head-to-head study compared a single monthly injection of ...

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...